These Analysts Boost Their Forecasts On Agilent After Upbeat Q4 Results
Nov 25, 2025, 1:26 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Agilent's strong earnings and improved EPS guidance positively indicate future performance, similar to past quarters where good earnings reports led to sustained share price increases.
AI summary
What happened, with direct paths to the underlying reporting
Agilent's Q4 earnings beat estimates with $1.59 per share. Quarterly sales of $1.861 billion surpassed expectations of $1.832 billion. FY2026 EPS guidance of $5.86 to $6.00 exceeds market estimate. Analysts increased price targets, with most maintaining positive ratings. Agilent shares rose 3.5% following the optimistic earnings report.
Agilent's Q4 earnings beat estimates with $1.59 per share.
Quarterly sales of $1.861 billion surpassed expectations of $1.832 billion.
FY2026 EPS guidance of $5.86 to $6.00 exceeds market estimate.
Analysts increased price targets, with most maintaining positive ratings.
Agilent shares rose 3.5% following the optimistic earnings report.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Agilent Technologies raised its full-year profit forecast, citing improving demand for its lab and medical research tools. The upbeat guidance points to sustained strength in life…
Agilent Technologies topped expectations for Q2 and lifted FY26 adjusted EPS guidance, signaling stronger demand for its instruments. The shares rose 17% to $135.92, helping lift…
Agilent Technologies increased its 2026 adjusted earnings guidance, citing robust demand for its life sciences instruments used in research and diagnostics. The upbeat outlook rei…
Agilent Technologies has announced its acquisition of Biocare Medical for $950 million, enhancing its pathology portfolio. This strategic move is expected to accelerate revenue gr…